EUCTR2017-003028-59-NL进行中（未招募）1 期
Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study - ATC-Anakinra1
Radboud University Medical Centre0 个研究点目标入组 10 人开始时间: 2018年3月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- newly diagnosed patients with a proven diagnosis (cytology or histology) of ATC, for whom surgery is not feasible.
- •- Patients with proven ATC (cytology or histology), presenting with metastasis not amendable for surgery.
- •- age = 18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •- unable to give informed consent
- •- pregnancy or breast feeding
- •- neutropenia (absolute neutrophil count (ANC)< 1.5 x10^9/l)
- •- patients with a known history of allergic reactions to compounds of similar chemical or biological composition to Anakinra.
- •- Any severe condition which could interfere with participation in this trial, including, but not limited to: severe renal dysfunction (creatinin clearance < 15 ml/min), severe cardiac failure, severe respiratory conditions etc.
- •- Active infection; However, after adequate treatment of infections, patients will be eligible for inclusion again.
研究者
相似试验
已完成
不适用
Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept studyNL-OMON46644Radboud Universitair Medisch Centrum10
尚未招募
不适用
Treatment with recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with anaplastic thyroid cancer: a proof of concept studyNL-OMON22269Radboud UMC Nijmegen, The Netherlands10
进行中（未招募）
2 期
The use of anakinra in treating complex regional pain syndrome by blocking interleukin-1Refractory complex regional pain syndromeNervous System DiseasesComplex regional pain syndromeISRCTN12908996niversity of Liverpool26
进行中（未招募）
1 期
BLOC-ICH; Could a new treatment improve recovery for patients who have had an intracerebral haemorrhageintracerebral haemorrhageMedDRA version: 20.0 Level: LLT Classification code 10022753 Term: Intracerebral haemorrhage System Organ Class: 100000004852EUCTR2018-000249-38-GBniversity of Manchester80
进行中（未招募）
1 期
Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes - MRC-ILA-HEART studyWe wish to investigate Acute coronary syndromes (ACS). These are caused by blockages in the main arteries that supply the heart as a result of a process called atherosclerosis. These blockages prevent blood flow down the artery and therefore prevent the heart muscle getting the blood and oxygen that it needs to survive and function. They account for 15% of all deaths in the UK and are associated with considerable long term consequences among survivors.MedDRA version: 8.1 Level: PT Classification code 10051592 Term: Acute coronary syndromeEUCTR2006-001767-31-GBniversity of Sheffield186